Kura Oncology Balance Sheet Health
Financial Health criteria checks 6/6
Kura Oncology has a total shareholder equity of $423.8M and total debt of $9.5M, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are $478.8M and $55.1M respectively.
Key information
2.2%
Debt to equity ratio
US$9.47m
Debt
| Interest coverage ratio | n/a |
| Cash | US$455.30m |
| Equity | US$423.77m |
| Total liabilities | US$55.07m |
| Total assets | US$478.84m |
Recent financial health updates
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?
Nov 01
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
May 08Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26Recent updates
Kura Oncology: A Contender In The Field Of Precision Medicine
Nov 21Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?
Nov 01Kura Oncology: The Long Holding Pattern Is Risky
Aug 12Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Jul 12Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
May 08Kura Oncology: Balancing Act Of Promise And Pragmatism
May 07Kura Oncology: Ziftomenib's Path To AML Market Widens
Jan 31Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price
Jan 25Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?
Jan 31Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
Jul 13We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Kura Oncology Investor Presentation - Slideshow
May 08What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?
Dec 14
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
Dec 10Kura Oncology (KURA) Presents At ASH Virtual Investor Event
Dec 08Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate
Dec 07Financial Position Analysis
Short Term Liabilities: KURA's short term assets ($463.2M) exceed its short term liabilities ($40.4M).
Long Term Liabilities: KURA's short term assets ($463.2M) exceed its long term liabilities ($14.7M).
Debt to Equity History and Analysis
Debt Level: KURA has more cash than its total debt.
Reducing Debt: KURA's debt to equity ratio has reduced from 3.2% to 2.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KURA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KURA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 20% each year